Drugs / Neo-MASCT
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03205930 | Aug 2017 → Oct 2019 | non-small cell lung carcinoma | The First People's Hospital of Lianyungang | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Neo-MASCT | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03205930 ↗ |
| Modality | Cell therapy | “Efficacy and safety of PD-1 blockade-activated neoantigen specific cellular therapy for advanced relapsed non-small cell lung cancer.” PMID 39751937 ↗ Jan 2025 |
| Route | Subcutaneous | “All participants received subcutaneous injection of mature dendritic cells(mDCs) loaded with neoantigens on day 8” PMID 39751937 ↗ Jan 2025 |